• Updated

To the editor: I attended U.S. Rep. Greg Walden’s town hall in The Dalles where health care was a hot topic of discussion. When Congress resumes work on the fiscal year 2017 budget, it’s important they reject the White House proposal to dramatically reduce funding for cancer research.

  • Updated

WASHINGTON — A high-ranking Senate Democrat is pushing for more answers on why doctors and patient advocates with financial ties to the pharmaceutical industry came to serve on a panel that advises the federal government on pain issues. Sen. Ron Wyden says he is “even more concerned” about these apparent conflicts of interest after receiving a response from the National Institutes of Health, which vetted and selected the panel members. In a letter sent Thursday to the Obama administration’s top health official, Wyden requests a series of documents related to the pain panel, including financial disclosure forms filled out by its members.